https://www.selleckchem.com/pr....oducts/hc-030031.htm
Net clinical adverse events were lower within 30days in the rivaroxaban group versus those in the only DAPT group and remained relatively low throughout the follow-up period. There were no significant differences in bleeding events between the 2 groups in 30days and 180days. However, 1 case of intracranial hemorrhage (major bleeding) occurred in the rivaroxaban group within 30days. Our results supported that the short-duration addition of low-dose rivaroxaban to DAPT could prevent LVT formation in patients with anterior STEMI followin
Like
Comment
Share
